Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin C Followed by Standard Chemotherapy in Treating Patients with Peritoneal Carcinomatosis

Inclusion Criteria

• Capable of providing informed consent
• The patient who has not previously received hyperthermic intraperitoneal chemotherapy must have histopathologically or cytologically confirmed cancer from peritoneal mesothelioma, pseudomyxoma, or gastrointestinal malignancies (excluding pancreatic and hepatobiliary) with known synchronous or metachronous disease dissemination limited to the peritoneal surfaces
• The patient must have documented disease limited to the peritoneal surface, amenable to complete cytoreduction indicated by: * Disease confined to the peritoneal surfaces * No parenchymal liver metastases * No evidence of clinical, biochemical or radiological biliary obstruction * Small volume of disease in the gastro-hepatic ligament defined by a < 5 cm mass in the epigastric region on cross-sectional imaging * No clinical or radiological evidence of hematogenous or distant nodal metastasis
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 1
• Absolute neutrophil count (ANC) > 1500/mm^3
• White blood cell count (WBC) > 4000/mm^3
• Platelet count > 100,000/mm^3
• An international normalized ratio (INR) =< 1.5 (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)
• Total serum bilirubin =< 1.5 mg/dl (patients with total bilirubin > 1.5 mg/dL eligible only with Gilbert’s syndrome)
• Alkaline phosphatase < 2.5 times the upper limit of normal
• Aspartate aminotransferase (AST) < 1.5 times upper limit of normal (alkaline phosphatase and AST cannot both exceed the upper limit of normal)
• Creatinine < 1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of >= 50ml/min
• Satisfactory cardiopulmonary function (no history of severe congestive heart failure or severe pulmonary disease, as indicated by clinically acceptable risks to undergo major abdominal - cytoreductive surgery)
• Patients who have met the above criteria and who have undergone CRS and HIPEC in the past 18 months for the forementioned disease processes without evidence of recurrence will be eligible for participation in this study for analyzing ability to achieve complete cytoreduction, morbidity, progression and survival

Exclusion Criteria

• The patients have documented disease beyond the peritoneal surfaces, which prevent achieving complete cytoreduction as indicated by: * Evidence of distant hematogenous metastatic disease or distant nodal metastases * Evidence of parenchymal hepatic metastases * Evidence of clinical, biochemical or radiological biliary obstruction * Evidence of gross disease of the small bowel mesentery characterized by distortion, thickening or loss of mesenteric vascular clarity which limits ability to obtain complete cytoreduction
• Significant history of a medical problem or co-morbidity that would preclude the patient from undergoing a major abdominal operation such as a history of severe congestive heart failure or active ischemic heart disease
• Active systemic infections, coagulation disorders, or other major medical illnesses precluding major surgery
• Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy or radiologic studies
• Significant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function tests (PFTs) indicating a forced expiratory volume in one second (FEV1) less than 50% or a diffusion capacity of carbon monoxide (DLCO) less than 40% predicted for age
• Psychiatric or addictive disorders or other conditions that would preclude the patient from meeting the study requirements
• Patients in pregnant or lactating
• Patients with a body mass index (BMI) of 40 or more